Reported Earnings • Jun 16
Full year 2026 earnings released: CA$1.03 loss per share (vs CA$0.49 profit in FY 2025) Full year 2026 results: CA$1.03 loss per share (down from CA$0.49 profit in FY 2025). Revenue: CA$320.6m (up 11% from FY 2025). Net loss: CA$58.6m (down 317% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Ankündigung • Jun 13
Aurora Cannabis Inc. Reports Impairment of Property, Plant and Equipment for the Fourth Quarter Ended March 31, 2026 Aurora Cannabis Inc. reported impairment of property, plant and equipment for the fourth quarter ended March 31, 2026. For the quarter, the company reported Impairment of property, plant and equipment of $2,246,000. Ankündigung • Jun 12
Aurora Cannabis Inc. Provides Earnings Guidance for 2027 Aurora Cannabis Inc. provided earnings guidance for 2027. Outlook reflects the strategic changes they have made in exiting low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus on global medical cannabis. They believe this is highest return opportunity to create value. Over the next few quarters, they are purposely investing in international business through strategic sales initiatives and EU GMP capacity expansion to support growth in most profitable markets. These efforts are expected to help offset the impact of margin reductions in Canadian medical business, following the reduction in government reimbursed pricing, effective April 1, 2026. Total Net Revenue is expected to decline and be more in line with Cannabis Net Revenue results in fiscal year 2025, following the changes in Canadian medical partially offset by international growth, driven by Germany and Poland. Ankündigung • May 28
Aurora Cannabis Inc. to Report Q4, 2026 Results on Jun 11, 2026 Aurora Cannabis Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 11, 2026 Ankündigung • May 22
Aurora Cannabis Inc., Annual General Meeting, Aug 07, 2026 Aurora Cannabis Inc., Annual General Meeting, Aug 07, 2026. Ankündigung • Apr 17
Aurora Cannabis Inc. (TSX:ACB) acquired Safari Flower Co. for CAD 28.8 million. Aurora Cannabis Inc. (TSX:ACB) acquired Safari Flower Co. for CAD 28.8 million on April 14, 2026. The consideration for the transaction consists of CAD 15 million in cash, subject to customary adjustments post-closing, issuance of 2.4 million Aurora common shares, and CAD 2 million that is contingent on satisfaction of certain conditions.
The transaction is expected to be accretive.
Aurora Cannabis Inc. (TSX:ACB) completed the acquisition of Safari Flower Co. on April 14, 2026. Ankündigung • Feb 11
Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand Aurora Cannabis Inc. is expanding its Aurora medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth. The expansion in New Zealand this month includes two new THC flower products - Big Wave, Night Ride, as well as the balanced strain, Half Moon™ coming soon in first quarter of fiscal year27. The brand will also debut four new resin cartridges in Australia this month including, Chemango Kush, Cosmic Cream, Lunar Express, and Soul Train Haze. Each new product is derived from Aurora's proprietary genetics, and manufactured at the company's leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety. New Zealand Launches: Big Wave™ - Flower, Hybrid, THC 26%, CBD; Night Ride™ - Flower, Indica, THC 29%, CBD; Half Moon™ - Flower, hybrid, THC 9%, CBD; Australia Launches: Chemango™ Kush - Resin Cartridge, Indica, THC 780mg/g, CBD. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Ankündigung • Feb 04
Aurora Cannabis Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Aurora Cannabis Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Ankündigung • Jan 22
Aurora Cannabis Inc. to Report Q3, 2026 Results on Feb 04, 2026 Aurora Cannabis Inc. announced that they will report Q3, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026 Ankündigung • Jan 14
Aurora Cannabis Inc. Announces Significant Progress in powdery mildew Disease Resistance Research Aurora Cannabis Inc. announced significant progress in its powdery mildew (PM) resistance research, nearly one year after the company's breakthrough discovery of a novel source of genetic resistance against powdery mildew, PM2. Since the initial discovery, Aurora has performed multiple rounds of crosses to transfer PM2 resistance into elite breeding lines. The research involves testing in breeding populations through controlled infection trials with high disease pressure, validating the durability and effectiveness of PM2 resistance. These trials are done to ensure that disease resistance is integrated into high-performing genetics without compromising quality traits, that are critical for patients and consumers globally. The company has recently shared its research at leading scientific and industry conferences, including the Plant & Animal Genome Conference, the Canadian Society for Horticultural Science & Canadian Society of Agronomy 2025 Conference, the 4th Annual Cannabis Scientific Symposium at the McGill Research Centre for Cannabis, and the PhotoX Conference. The proprietary genetic marker technology behind PM2 was developed by scientists at Aurora Coast, the company's world-class research and development facility, and builds from Aurora's previous collaboration with researchers at the University of British Columbia and research funding from Genome British Columbia. Should the production trials be successful, the company will look to commercialize PM-resistance cultivars later this year, which will protect plant health, reduce operational costs and improve product quality. As a global medical cannabis company enabled by science, Aurora continues to push the boundaries of cannabis science. By integrating advanced breeding techniques with rigorous research, Aurora is setting new standards for quality and efficiency, all while creating a strong production network to support existing and future markets. This intellectual property is currently patent pending in Canada, United States, Europe, Australia, New Zealand, and Israel. Ankündigung • Oct 23
Aurora Cannabis Inc. to Report Q2, 2026 Results on Nov 05, 2025 Aurora Cannabis Inc. announced that they will report Q2, 2026 results Pre-Market on Nov 05, 2025 Ankündigung • Aug 14
Aurora Cannabis Inc. Announces Executive Changes Aurora Cannabis Inc. announced that Theresa Firestone resigned from Aurora's Board of Directors effective August 31, 2025. Ms. Firestone was first appointed to the Aurora Board in 2021 and most recently served as Chair of the Human Resources and Compensation Committee (the "HRCC"). Immediately following the Meeting, and in addition to ratifying Michael Singer as the new Lead Independent Director, the Board has appointed Michael Singer to the role of Chair of the HRCC. Ankündigung • Aug 08
Aurora Cannabis Inc. Provides Consolidated Earnings Guidance for the Second Quarter of 2026 Aurora Cannabis Inc. provided consolidated earnings guidance for the second quarter of 2026. for the quarter, the company expects net revenue increase year over year, driven primarily by 8% to 12% growth in its Global Medical Cannabis segment. Ankündigung • Jul 24
Aurora Cannabis Inc. to Report Q1, 2026 Results on Aug 06, 2025 Aurora Cannabis Inc. announced that they will report Q1, 2026 results Pre-Market on Aug 06, 2025 Ankündigung • Jun 26
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program Aurora Cannabis Inc. have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 for Aurora patients through AuroraMedical.com. The changes to the compassionate pricing program are available alongside new medical cannabis products, including: Aurora | Mediora Minis - Cannatonic CBD Flower, Sativa (10mg); Daily Special | Sativa J's - THC Pre-Rolls, Sativa (7 x 0.3g); WMMC | Seasonal Stash Petro Biscuit - THC Flower, Indica (10mg). In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit for more information and to connect with the Aurora client care team for further support. Ankündigung • Jun 05
Aurora Cannabis Inc. Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22 Aurora Cannabis Inc. has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new Cultivars available include: IndiMed TEM PO 22 | Lemon Laser - Sativa, 22% THC, IndiMed TEMPO22 | Pickled Petrol - Indica, 22% THC, Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. Ankündigung • Jun 04
Aurora Cannabis Inc. to Report Q4, 2025 Results on Jun 18, 2025 Aurora Cannabis Inc. announced that they will report Q4, 2025 results Pre-Market on Jun 18, 2025 Ankündigung • May 26
Aurora Cannabis Inc., Annual General Meeting, Aug 08, 2025 Aurora Cannabis Inc., Annual General Meeting, Aug 08, 2025. Ankündigung • Apr 15
Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom Aurora Cannabis Inc. has announced the availability of medical cannabis concentrates to patients in the United Kingdom (UK). This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the UK market. These products are available to patients in Canada and Australia and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally. The two novel cultivar-specific Aurora 1.2g resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for fast and controlled delivery of medical cannabis. Key benefits of cannabis inhalers include: Exceptional Flavour Profiles: Connected to popular flower products, these strain-specific cartridges use high-quality terpenes and pure extracts to deliver rich and authentic flavours; High Potency: Ensures a powerful, consistent, controllable experience with each dose; Safety and Quality: Manufactured in facilities, adhering to strict TGA-GMP quality control and safety standards. These cartridges contain no additives, representing the pinnacle of cannabis purity; User-Friendly Design: Easy to use, making it a convenient, portable and discreet choice for patients. Aurora's portfolio of cannabis products is available nationwide for cannabis retailers to offer. Patients may contact their clinic for further information or consult their doctor. Ankündigung • Mar 20
Aurora Cannabis Inc. Announces the Discovery of a Novel Source of Genetic Resistance Against Powdery Mildew, PM2 Aurora Cannabis Inc. announced the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year. In the peer reviewed research lead by Jose Celedon, Principal Scientist of Breeding and Genetics at Aurora, in collaboration with researchers at The University of British Columbia, it is noted that, " breeding genetic resistance to economically important crop diseases is the most sustainable strategy for disease management and enhancing agricultural and horticultural productivity, particularly where the application of synthetic pesticides is prohibited" (Seifi, et al.) The discovery of PM2 will further the company's mission to enhance the biosecurity of production facilities, reduce production costs, and improve product quality. As a global medical cannabis company enabled by science, Aurora's dedication to scientific research and innovation has led to remarkable advancements, notably boosting potency and yield. These improvements have overall reduced costs and increased efficiency. This cutting-edge genetic research and development differentiates Aurora from others in the industry, as it aims to surpass traditional breeding limitations, leading to advanced cultivation methods and new market opportunities worldwide. Ankündigung • Feb 21
Aurora Cannabis Inc. Expands Medical Cannabis Pastille Offerings in Australia Aurora Cannabis Inc. has announced the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests. Medical cannabis pastilles offer several key benefits, including easy oral intake. The prolonged effects provide long-lasting and extended relief after digestion. Pastilles also come in an accessible format that is discrete, portable, and convenient. The pastilles that are now available in Australia include: Aurora Pastilles - 10mg THC Pomegranate Berry (30 pack) Aurora Pastilles - 10:10 Balanced Pineapple (30 pack) Aurora Pastille - 25mg CBD Acai Berry (30 pack) Aurora maintains its position as the largest global medical cannabis company operating in nationally legal markets. The company has a robust innovation pipeline planned for global introduction over the course of the coming months, bringing variety and new options to patients. Ankündigung • Feb 07
Aurora Cannabis Inc. Reports Unaudited Consolidated Impairment of Property, Plant and Equipment for the Third Quarter Ended December 31, 2024 Aurora Cannabis Inc. reported unaudited consolidated impairment of property, plant and equipment for the third quarter ended December 31, 2024. For the quarter, the company reported impairment of property, plant and equipment of CAD 567,000. Ankündigung • Jan 23
Aurora Cannabis Inc. to Report Q3, 2025 Results on Feb 05, 2025 Aurora Cannabis Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 05, 2025 Ankündigung • Nov 21
Aurora Cannabis Inc. Expands Innovative Recreational Product Portfolio Aurora Cannabis Inc. announced its latest lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands. With a continued focus on premium, science-driven offerings, this expanded lineup represents Aurora's commitment to delivering exceptional high quality, cutting-edge and diverse options for Canadian cannabis consumers. Aurora boasts a leading portfolio of brands that Canadians know and love, including Greybeard, San Rafael ' 71 and Tasty's. Following Tasty's inaugural year in the Canadian adult market, the brand leaned into valuable consumer insights to develop. The new offerings reinforce Tasty's commitment to quality, creativity, and an unforgettable cannabis experience. The latest products available across Canada include the following: Greybeard | Banana GasPure Live Resin Vape, awakens senses with authentic notes of gassy bananas on the inhale and a savoury, umami finish on the exhale. Greybeard | Country Lemon Terp Slush (1g); live resin extract featuring a bright, golden hue and a smooth, suugary texture. Greybeard | Critical Diesel Pre-Rolls (3 x 0.5g); crafted from 100% whole milled bud, not trim, these pre-rolls are an effortless way to experience Greybeard's latest craft sativa - known for its unique blend of cherry, grape, strawberry, vanilla and gas aromas. San Rafael '71 | 20 Pack Pre-Rolls (20 x 0.5g); made in response to the growing demand for bulk pre-roll options; perfect for those who appreciate consistency and value. Tasty's | Mango Diamond Infused Pre-Rolls, Indica (3 x 0.5 g), infused with ultra- powerful THC-A diamonds, with a burst of tangy, sun-kissed mango flavours enhanced by botanical terpenes. Tasty's | Honeydew Diamond Infused Pre- Rolls, Sativa (3 x 0.5G), infused with THC-A diamonds, with ripe, refreshing honeydew flavour. Tasty's | Melon Diamond Infused Pre-Rolling Pre-Rolls, Sativa (3x 0.5g), created with THC-A diamonds and refreshing sweet melon flavours. Tasty's | Grape 510 Vape (1.2g), offers an unbeatable combination of taste and 1000mg of THC to deliver a tangling sweetness with subtle tanginess. Aurora's portfolio of cannabis products are made available nationwide for cannabis retailers to offer. New Risk • Nov 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$30m Forecast net loss in 1 year: CA$409k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$409k net loss next year). Share price has been volatile over the past 3 months (9.1% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Breakeven Date Change • Nov 09
Forecast to breakeven in 2026 The 6 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 75% to 2025. The company is expected to make a profit of CA$2.59m in 2026. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Ankündigung • Nov 08
Aurora Cannabis Inc. Announces Notice of Proposed Settlement of Class Action Involving All Persons and Entities Who Purchased Aurora Cannabis Inc. Common Stock Between October 23, 2018 and February 28, 2020, Inclusive Aurora Cannabis Inc. announces that hearing will be held on January 28, 2025, at 2:00 p.m., before the Honorable James B. Clark, III at the United States District Court, District of New Jersey, Frank R. Lautenberg Post Office & U.S. Courthouse, 2 Federal Square, Newark, New Jersey 07102, to determine whether: (1) the proposed settlement (the "Settlement") of the above-captioned Litigation as set in the Stipulation of Settlement ("Stipulation")[1] for $8.05 million in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Plaintiffs' Counsel attorneys' fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action ("Notice"), which is discussed below) and, if so, in what amounts; (4) to reimburse Lead Plaintiffs for their time and expenses in connection with their representation of the Settlement Class and, if so, in what amounts; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate. To share in the distribution of the Net Settlement Fund, one must establish rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail (postmarked no later than February 27, 2025) or electronically via the website (no later than February 27, 2025). Reported Earnings • Nov 08
Second quarter 2025 earnings released: EPS: CA$0.05 (vs CA$0.048 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.05 (up from CA$0.048 in 2Q 2024). Revenue: CA$81.1m (up 28% from 2Q 2024). Net income: CA$2.60m (up 40% from 2Q 2024). Profit margin: 3.2% (up from 2.9% in 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Ankündigung • Oct 25
Aurora Cannabis Inc. to Report Q2, 2025 Results on Nov 06, 2024 Aurora Cannabis Inc. announced that they will report Q2, 2025 results Pre-Market on Nov 06, 2024 Ankündigung • Sep 21
Aurora Cannabis Inc. Announces Board Changes and Changes to Board Committee Compositions Aurora Cannabis Inc. announced the appointments of CEO Miguel Martin to the additional role of executive chairman and outgoing chairman Ron Funk as lead independent director. Both are backed by unanimous votes by the company's board of director and are effective immediately. Martin has led Aurora as CEO and a director since 2020, driving the company's financial recovery and successful business transformation. Changes to Board Committee Compositions: Michael Singer, who previously acted as executive chairman and interim CEO, was appointed to the Audit Committee and the Human Resource and Compensation Committee. Rajesh Uttamchandani was appointed to the HRCC and the Nominating and Corporate Governance Committee. Reported Earnings • Aug 08
First quarter 2025 earnings released: EPS: CA$0.12 (vs CA$0.59 loss in 1Q 2024) First quarter 2025 results: EPS: CA$0.12 (up from CA$0.59 loss in 1Q 2024). Revenue: CA$83.4m (up 11% from 1Q 2024). Net income: CA$6.22m (up CA$27.0m from 1Q 2024). Profit margin: 7.5% (up from net loss in 1Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Ankündigung • Jul 29
Aurora Cannabis Inc. to Report Q1, 2025 Results on Aug 07, 2024 Aurora Cannabis Inc. announced that they will report Q1, 2025 results Pre-Market on Aug 07, 2024 New Risk • Jun 27
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$55m Forecast net loss in 3 years: CA$6.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$6.0m net loss in 3 years). Breakeven Date Change • Jun 21 The 6 analysts covering Aurora Cannabis previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 86% to 2025. The company is expected to make a profit of CA$6.39m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Reported Earnings • Jun 21
Full year 2024 earnings released: CA$1.28 loss per share (vs CA$8.22 loss in FY 2023) Full year 2024 results: CA$1.28 loss per share (improved from CA$8.22 loss in FY 2023). Revenue: CA$270.3m (up 16% from FY 2023). Net loss: CA$55.3m (loss narrowed 79% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Ankündigung • May 16
Aurora Cannabis Inc. Appoints Rajesh Uttamchandani to its Board of Directors Aurora Cannabis Inc. announced the appointment of Rajesh Uttamchandani to the Company's Board of Directors, effective May 15, 2024. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leading businesses in emerging technology, FinTech, human capital consulting and global education. Most recently, he was the Chief People Officer for ApplyBoard. Previous roles include serving as Chief Operating Officer and Chief People Officer at MaRs Discovery District and Chief Human Resources Officer and Managing Director at Zafin. Mr. Uttamchandani brings to Aurora a wealth of experience as current and past Director for private and public organizations, including LifeSpeak, Ontario Cannabis Stores, Mackenzie Health, and several not-for-profit organizations. Mr. Uttamchandani holds several degrees and professional designations, including a Master of Industrial Relations and Human Resources from University of Toronto; a Juris Doctor from Osgoode Hall Law School; and an L.L.M in Employment and Labour, also from Osgoode Hall Law School. He is a holder of the Institute of Corporate Directors Director designation (ICD.D) and is a lawyer called to the Bar of Ontario. Ankündigung • Apr 30
Aurora Cannabis Inc. in Conjunction with MedReleaf Australia, Announce Expansion of its Portfolio with Introduction of New Range of Premium Dried Cannabis Flower Products Aurora Cannabis Inc. in conjunction with MedReleaf Australia, announced the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia. The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including: Aurora Moon Berry T9/C13 Balanced; Aurora Black Jelly T28/C1 Sativa; Aurora Chemango Kush T29/C1 Indica; and Aurora Vespera T1/C17 CBD. The expanded range of Aurora products caters to the market demand for more affordable options without compromising on quality. With a focus on sustainability, the 2.0 genetics employed in these cultivars ensure reliable large-scale cultivation to meet market demand while maintaining elevated quality standards. Furthermore, the MedReleaf Australia family of brands now focuses on three core brands - CraftPlant, offering a hand-crafted, premium range of products; Aurora, for innovative and affordable options; and IndiMed, providing a company-funded concession range. Ankündigung • Feb 20
Aurora Cannabis Inc. Announces CFO Changes Aurora Cannabis Inc. announced that Simona King, a former executive of Bristol Myers-Squibb, a leading multinational pharmaceutical company, has been appointed as Chief Financial Officer of the Company, effective February 21, 2024. Ms. King brings over 25 years of progressive finance leadership experience, with deep business knowledge and proven success with global and emerging organizations. She served nearly 20 years with Bristol Myers-Squibb, where she held increasingly senior finance roles and enabled the company's growth strategy. Glen Ibbott, current Chief Financial Officer, will be stepping down from his full-time role effective 20 February 2024, to pursue new opportunities. He will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Simona. Ms. King brings deep financial expertise across corporate, operations and international business units. In recent years, she has spread her professional reach, joining fast moving public companies in emerging sectors, including biotech. She joins Aurora most recently as the CFO of a number of clinical stage biotechnology companies. New Risk • Feb 14
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 76% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 76% per year for the foreseeable future. High level of non-cash earnings (104% accrual ratio). Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). New Risk • Feb 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$1.7b Forecast net loss in 3 years: CA$2.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$2.8m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding). Ankündigung • Feb 09
Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million. Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million on February 7, 2024.The consideration should be paid in approximately AUD$9.5 million in cash and the remainder by the issuance of Common Shares. The transaction is subject to customary adjustments.Aurora Cannabis Inc. (TSX:ACB) completed the acquisition of remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million on February 7, 2024. Ankündigung • Feb 08
Aurora Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of Fiscal 2024 Aurora Cannabis Inc. provided earnings guidance for the fourth quarter of fiscal 2024. For the quarter, company expects revenue from Canadian medical and consumer segments to be steady quarter over quarter, while Europe and Australia should provide modest growth in their regions and Revenue increases combined with ongoing cost control are expected to result in continued positive. Ankündigung • Feb 01
Aurora Cannabis Inc. to Report Q3, 2024 Results on Feb 08, 2024 Aurora Cannabis Inc. announced that they will report Q3, 2024 results Pre-Market on Feb 08, 2024 Ankündigung • Nov 11
Aurora Cannabis Inc. Provides Revenue Guidance for Third Quarter of Fiscal 2024 Aurora Cannabis Inc. Provided Revenue Guidance for third quarter of fiscal 2024. For the period, the company expects cannabis revenue to be largely similar to fiscal second quarter, 2024, with the geographical mix slightly weighted further towards the international medical segment. For plant propagation, company expect to see seasonally reduced revenues and gross profit in fiscal third quarter 2024 that will be consistent with fiscal second quarter 2024 and in line with historical performance. Ankündigung • Oct 27
Aurora Cannabis Inc. to Report Q2, 2024 Results on Nov 09, 2023 Aurora Cannabis Inc. announced that they will report Q2, 2024 results After-Market on Nov 09, 2023 New Risk • Oct 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Ankündigung • Oct 05
Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million. Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 53,187,500
Price\Range: CAD 0.73
Discount Per Security: CAD 0.0365 Ankündigung • Aug 11
Aurora Cannabis Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024 Aurora Cannabis Inc. provided revenue guidance for the second quarter of fiscal year 2024. For the quarter, the company expects cannabis net revenue to be largely similar to fiscal first quarter 2024, with the geographical mix slightly weighted further towards the international medical segment. For plant propagation, the company expects to see seasonally reduced revenues in second quarter 2024 that will be in line with historical performance as 25% – 35% of revenues are normally earned in the second half of a calendar year. Buying Opportunity • Aug 07
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be €0.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 67%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Ankündigung • Jul 29
Aurora Cannabis Inc. to Report Q1, 2024 Results on Aug 10, 2023 Aurora Cannabis Inc. announced that they will report Q1, 2024 results After-Market on Aug 10, 2023 Ankündigung • Jul 25
Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million. Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million on July 21, 2023. Up to CAD 15 million could be payable over time by Bevo Farms to Aurora in connection with the Aurora Sun Transaction, based on Bevo Farms successfully achieving certain financial milestones at the Aurora Sun Facility.
Bevo Farms Ltd completed the acquisition of Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) on July 21, 2023. Buying Opportunity • Jul 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be €0.64, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 67%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Recent Insider Transactions • Jun 25
CEO & Director recently bought €90k worth of stock On the 20th of June, Miguel Martin bought around 179k shares on-market at roughly €0.50 per share. This transaction amounted to 92% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Miguel's only on-market trade for the last 12 months. New Risk • Jun 23
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$818m Forecast net loss in 3 years: CA$9.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$9.4m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Reported Earnings • Jun 15
Third quarter 2023 earnings released: CA$0.24 loss per share (vs CA$4.72 loss in 3Q 2022) Third quarter 2023 results: CA$0.24 loss per share (improved from CA$4.72 loss in 3Q 2022). Revenue: CA$64.0m (up 27% from 3Q 2022). Net loss: CA$82.0m (loss narrowed 92% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Ankündigung • Jun 09
Aurora Cannabis Inc. to Report Fiscal Year 2023 Results on Jun 14, 2023 Aurora Cannabis Inc. announced that they will report fiscal year 2023 results Pre-Market on Jun 14, 2023 New Risk • Jun 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$14m net loss in 3 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Ankündigung • Jun 07
Aurora Celebrates Summer with New Innovation Launching Across Canada Aurora Cannabis Inc. is launching a fresh lineup of innovative products, available to patients on Aurora Medical and consumers, at retailers across the country this summer. The company's ever-expanding portfolio includes new 1mg format, snackable edibles, premium resin vape carts with big, bold flavour, and a true-to-form signature hash. New flower products include Chemango Kush, an original strain from Occo, Aurora's esteemed breeding program, as well as 14g format extensions on popular strains, Moon Berry and Pink Diesel. In addition to leveraging Aurora's best-in-class genetics breeding and research program, the company has launched Aurora Lab, an exclusive experiential research and education program designed to strengthen two-way conversations with patients, retailers, budtenders and consumers. Through Aurora Lab, partners get behind-the-scenes access and sneak peeks at new products and formats, while invited patients get a chance to trial unreleased products in exchange for feedback. Insights gleaned from the program will be used to develop future products and inform Aurora's innovation pipeline. Ankündigung • May 26
Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023 Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023. Breakeven Date Change • Mar 31
Forecast to breakeven in 2026 The 8 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$1.50m in 2026. Average annual earnings growth of 45% is required to achieve expected profit on schedule. Ankündigung • Feb 11
Aurora Cannabis Inc. Reports Impairment Changes for the Quarter Ended December 31, 2022 Aurora Cannabis Inc. reported impairment changes for the quarter ended December 31, 2022. For the quarter, the company reported impairment of property, plant and equipment of CAD 2,259,000 against CAD 4,281,000 a year ago. Reported Earnings • Feb 10
Second quarter 2023 earnings released: CA$0.20 loss per share (vs CA$0.38 loss in 2Q 2022) Second quarter 2023 results: CA$0.20 loss per share (improved from CA$0.38 loss in 2Q 2022). Revenue: CA$61.7m (up 1.8% from 2Q 2022). Net loss: CA$65.4m (loss narrowed 13% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 6 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Buying Opportunity • Feb 10
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 43%. The fair value is estimated to be €1.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings is also forecast to grow by 47% per annum over the same time period. Ankündigung • Jan 27
Aurora Cannabis Inc. to Report Q2, 2023 Results on Feb 09, 2023 Aurora Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Feb 09, 2023 Buying Opportunity • Jan 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 30%. The fair value is estimated to be €1.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to grow by 18% per annum. Earnings is also forecast to grow by 48% per annum over the same time period. Ankündigung • Jan 05
An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million. An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million on January 4, 2023.An Unknown buyer completed the acquisition of Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million on January 4, 2023. Buying Opportunity • Dec 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 28%. The fair value is estimated to be €1.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to grow by 18% per annum. Earnings is also forecast to grow by 49% per annum over the same time period. Breakeven Date Change • Nov 16
Forecast to breakeven in 2025 The 5 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 80% per year to 2024. The company is expected to make a profit of CA$32.0m in 2025. Average annual earnings growth of 47% is required to achieve expected profit on schedule. Reported Earnings • Nov 12
First quarter 2023 earnings released: CA$0.17 loss per share (vs CA$0.06 loss in 1Q 2022) First quarter 2023 results: CA$0.17 loss per share (further deteriorated from CA$0.06 loss in 1Q 2022). Revenue: CA$49.3m (down 18% from 1Q 2022). Net loss: CA$51.6m (loss widened 334% from 1Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 6 years, compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Sep 22
Full year 2022 earnings released: CA$7.99 loss per share (vs CA$4.09 loss in FY 2021) Full year 2022 results: CA$7.99 loss per share (further deteriorated from CA$4.09 loss in FY 2021). Revenue: CA$221.3m (down 9.8% from FY 2021). Net loss: CA$1.72b (loss widened 148% from FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Recent Insider Transactions • Jun 03
Independent Director recently bought €62k worth of stock On the 31st of May, Chitwant Kohli bought around 40k shares on-market at roughly €1.55 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €61k more in shares than they have sold in the last 12 months. Reported Earnings • May 14
Third quarter 2022 earnings released: CA$4.72 loss per share (vs CA$0.83 loss in 3Q 2021) Third quarter 2022 results: CA$4.72 loss per share (down from CA$0.83 loss in 3Q 2021). Revenue: CA$50.4m (down 8.6% from 3Q 2021). Net loss: CA$1.01b (loss widened CA$851.6m from 3Q 2021). Over the next year, revenue is forecast to grow 12%, compared to a 7.1% growth forecast for the industry in Germany. Board Change • Mar 29
High number of new directors Independent Director Chitwant Kohli was the last director to join the board, commencing their role in 2022. Reported Earnings • Feb 11
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Second quarter 2022 results: CA$0.38 loss per share (up from CA$1.74 loss in 2Q 2021). Revenue: CA$60.6m (down 11% from 2Q 2021). Net loss: CA$74.8m (loss narrowed 75% from 2Q 2021). Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 19%, compared to a 7.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. Board Change • Feb 02
High number of new directors Independent Director Chitwant Kohli was the last director to join the board, commencing their role in 2022. Ankündigung • Feb 02
Aurora Cannabis Inc. to Report Q2, 2022 Results on Feb 10, 2022 Aurora Cannabis Inc. announced that they will report Q2, 2022 results After-Market on Feb 10, 2022 Reported Earnings • Nov 10
First quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.90 loss in 1Q 2021) The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2022 results: Revenue: CA$60.1m (down 11% from 1Q 2021). Net loss: CA$11.9m (loss narrowed 89% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has fallen by 54% per year, which means it is performing significantly worse than earnings. Reported Earnings • Sep 28
Full year 2021 earnings released: CA$4.09 loss per share (vs CA$33.84 loss in FY 2020) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: CA$245.3m (down 12% from FY 2020). Net loss: CA$692.0m (loss narrowed 79% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 5 percentage points per year. Ankündigung • Jun 10
Aurora Cannabis Expands San Rafael '71 Portfolio with the Launch of Three New Proprietary Cultivars for Canadian Consumer Market Aurora Cannabis Inc. announced the launch of three new proprietary cultivars under the Company's premium adult-use cannabis brand San Rafael '71: Stonefruit Sunset, Lemon Rocket and Driftwood Diesel. Guided by consumer insights to identify highly desirable traits, the new cultivars were developed at Aurora Coast, the Company's research facility dedicated to cannabis breeding, and home to one of the large and most comprehensive genetic libraries in the world. The new hybrid and indica cultivars are also the first adult-use flower products Aurora has commercialized from Aurora Coast. As with all San Rafael '71 premium dried flower products, new Stonefruit Sunset, Lemon Rocket and Driftwood Diesel are cultivated under the high quality standards and are hang dried and hand bottled for excellent quality. Each jar is packaged with a humidity pack to preserve the moisture of the flower, keeping the product fresher for longer. San Rafael '71 flower is known for its intense and appealing aromas, and these new cultivars will deliver on that brand promise. The new product offerings will be available for purchase across Canada starting in July. Stonefruit Sunset: Derived from Gelato and Fuel cultivars, Stonefruit Sunset is a hybrid strain with 19-25% THC, offering a unique aroma of berries, sherbet, and gas from its primary terpenes, Caryophyllene, Limonene and Myrcene. This strain is characterized by purple and green buds with bright orange pistils. Lemon Rocket: A cross of Fuel and Cake, Lemon Rocket is a hybrid strain with 20%+ THC and gives off a very pungent aroma of gas with hints of lemon from its primary terpenes, Limonene, Caryophyllene and Myrcene. This strain is characterized by bright-green buds coated in visible trichomes. Driftwood Diesel: A mix of GMO and Fuel cultivars, Driftwood Diesel is an indica strain with 21-27% THC and gives off a very strong and distinct aroma of gas and chem and sour taste with earthy, nutty and musky notes. This strain is distinguished by dark purple and green buds that are notably very sticky with visible trichomes. Reported Earnings • May 17
Third quarter 2021 earnings released: CA$0.85 loss per share (vs CA$1.34 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: CA$55.2m (down 25% from 3Q 2020). Net loss: CA$164.7m (loss widened 23% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 12
Second quarter 2021 earnings released: CA$1.74 loss per share (vs CA$14.17 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$67.7m (up 21% from 2Q 2020). Net loss: CA$292.8m (loss narrowed 77% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. Analyst Estimate Surprise Post Earnings • Feb 12
Revenue misses expectations Revenue missed analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 25%, compared to a 2.5% growth forecast for the Pharmaceuticals industry in Germany. Is New 90 Day High Low • Feb 03
New 90-day high: €10.45 The company is up 170% from its price of €3.87 on 04 November 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.62 per share. Ankündigung • Jan 28
Aurora Cannabis Inc. has completed a Composite Units Offering in the amount of $125.4 million. Aurora Cannabis Inc. has completed a Composite Units Offering in the amount of $125.4 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 12,000,000
Price\Range: $10.45
Discount Per Security: $0.496375 Recent Insider Transactions • Dec 08
Chief Science Officer recently bought €3.0m worth of stock On the 1st of December, Jonathan Page bought around 468k shares on-market at roughly €6.47 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €16m more in shares than they bought in the last 12 months. Ankündigung • Nov 26
Aurora Cannabis Inc. Announces Israeli Medical Supply Agreement with Cantek Holdings Aurora Cannabis Inc. announced it has entered into a strategic Supply Agreement (the "Agreement") with Cantek Holdings. Under the terms of the Agreement, Aurora will supply Cantek with dried bulk flower over a two-year period, with the option to extend. The Company intends to provide Cantek with a minimum of 4,000 kgs of bulk dried flower annually, which will be processed into finished product, and co-branded under the Aurora and Cantek brand names for the Israeli market with the potential for additional international market sales. Having secured all necessary export and import permits, the initial shipment of cannabis under the Agreement occurred during the week of November 16, 2020. Ankündigung • Nov 21
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aurora Cannabis, Inc Glancy Prongay & Murray LLP reminded investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aurora Cannabis Inc. securities between February 13, 2020 and September 4, 2020, inclusive. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company's purported "business transformation plan" and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that the company would record significant goodwill and asset impairment charges; and (4) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Analyst Estimate Surprise Post Earnings • Nov 10
Revenue beats expectations Revenue exceeded analyst estimates by 6.4%. Over the next year, revenue is forecast to grow 25%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Ankündigung • Nov 10
Former Founding Owner of Aurora Larssen Projects Ltd. acquired Aurora Larssen Projects Ltd.from Aurora Cannabis Inc. (TSX:ACB). Former Founding Owner of Aurora Larssen Projects Ltd. acquired Aurora Larssen Projects Ltd.from Aurora Cannabis Inc. (TSX:ACB) on May 11, 2020.
Former Founding Owner of Aurora Larssen Projects Ltd. completed the acquisition of Aurora Larssen Projects Ltd.from Aurora Cannabis Inc. (TSX:ACB) on May 11, 2020. Ankündigung • Oct 29
Aurora Cannabis Inc. to Report Q1, 2021 Results on Nov 09, 2020 Aurora Cannabis Inc. announced that they will report Q1, 2021 results at 9:00 AM, Eastern Standard Time on Nov 09, 2020 Is New 90 Day High Low • Oct 29
New 90-day low: €3.40 The company is down 62% from its price of €9.05 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.03 per share. Ankündigung • Oct 13
Rosen Law Firm Reminds Investors of Important Deadline in Securities Class Action Against Aurora Cannabis Inc Rosen Law Firm reminds purchasers of the securities of Aurora Cannabis Inc. between February 13, 2020 and September 4, 2020, inclusive, of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; the Company purported business transformation plan and cost reset failed to mitigate the foregoing issues; accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and as a result, the Company public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. 
